Behcet's disease in a patient with chronic myelogenous leukemia under hydroxyurea treatment: a case report and review of the literature.
Behcet's disease (BD) is a chronic, relapsing vasculitis of unknown etiology. Its association with chronic myelogenous leukemia (CML) is extremely rare, and typical manifestations of BD were observed in a very few patients with CML, mainly under interferon-alpha (IFN-alpha) treatment. Skin pathergy test, being positive in about 50% of patients with BD, is also positive in some IFN-alpha-treated patients with CML without any evidence of BD symptoms. We describe a 62-year-old woman with CML who developed characteristic features of BD, including a positive skin hyperactivity test, during treatment with hydroxyurea. Hydroxyurea has been implicated in the appearance of skin vasculitic ulceration, but this is the first case, according to our knowledge, where the development of BD was observed during hydroxyurea maintenance in the chronic phase of CML.
Vaiopoulos
G
G
First Department of Internal Medicine, University of Athens Medical School, Laiko General Hospital, Greece.
Terpos
E
E
Viniou
N
N
Nodaros
K
K
Rombos
J
J
Loukopoulos
D
D
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001528:Behcet Syndrome / Q000139:chemically induced / Q000150:complications*; D017809:Fatal Outcome; D005260:Female; D015235:HLA-B Antigens / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D012882:Skin Tests
D000970:Antineoplastic Agents; D015235:HLA-B Antigens; C035270:HLA-B5 antigen; D006918:Hydroxyurea